Promising lymphoma combo trial pulled before starting
NCT ID NCT07030699
First seen Jan 05, 2026 · Last updated May 20, 2026 · Updated 26 times
Summary
This study was designed to see if combining three drugs—epcoritamab, lenalidomide, and tafasitamab—could safely and effectively treat people with diffuse large B-cell lymphoma (DLBCL) that had come back or stopped responding to treatment. The trial was withdrawn before enrolling any participants, so no results are available. It was planned for adults aged 18 and older with certain types of B-cell lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.